Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain

The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030